187 related articles for article (PubMed ID: 24939490)
1. Dalbavancin approved for acute skin infections.
Traynor K
Am J Health Syst Pharm; 2014 Jul; 71(13):1062. PubMed ID: 24939490
[No Abstract] [Full Text] [Related]
2. Dalbavancin (Dalvance) for the treatment of acute bacterial skin infection.
Gupta AK; Foley KA; Abramovits W; Rosen T
Skinmed; 2014; 12(6):366-9. PubMed ID: 25823083
[No Abstract] [Full Text] [Related]
3. FDA approves Dalvance to treat skin infections.
Clin Infect Dis; 2014 Jul; 59(2):i. PubMed ID: 25105184
[No Abstract] [Full Text] [Related]
4. Antimicrobial development in the era of emerging resistance.
Sorlozano A; Carrasco C; Cabeza J; Villegas E; Gutierrez J
Mini Rev Med Chem; 2009 Jul; 9(8):938-55. PubMed ID: 19601889
[TBL] [Abstract][Full Text] [Related]
5. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies.
Dunne MW; Talbot GH; Boucher HW; Wilcox M; Puttagunta S
Drug Saf; 2016 Feb; 39(2):147-57. PubMed ID: 26715497
[TBL] [Abstract][Full Text] [Related]
6. Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Scott LJ
Drugs; 2015 Jul; 75(11):1281-91. PubMed ID: 26105117
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.
Dunne MW; Puttagunta S; Giordano P; Krievins D; Zelasky M; Baldassarre J
Clin Infect Dis; 2016 Mar; 62(5):545-51. PubMed ID: 26611777
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Ramdeen S; Boucher HW
Expert Opin Pharmacother; 2015; 16(13):2073-81. PubMed ID: 26239321
[TBL] [Abstract][Full Text] [Related]
9. Dalbavancin.
Anderson VR; Keating GM
Drugs; 2008; 68(5):639-48; discussion 649-51. PubMed ID: 18370443
[TBL] [Abstract][Full Text] [Related]
10. Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections.
Bell AM; King ST; Barber KE; Adcock KG; Wagner JL; Stover KR
Nurse Pract; 2018 Oct; 43(10):31-37. PubMed ID: 30153191
[TBL] [Abstract][Full Text] [Related]
11. Dalbavancin: a review.
Scheinfeld N
Drugs Today (Barc); 2007 May; 43(5):305-16. PubMed ID: 17724497
[TBL] [Abstract][Full Text] [Related]
12. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
[TBL] [Abstract][Full Text] [Related]
13. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
Roberts KD; Sulaiman RM; Rybak MJ
Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
[TBL] [Abstract][Full Text] [Related]
14. Once-weekly dalbavancin versus daily conventional therapy for skin infection.
Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW
N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082
[TBL] [Abstract][Full Text] [Related]
15. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections.
Dunne MW; Zhou M; Darpo B
Int J Antimicrob Agents; 2015 Apr; 45(4):393-8. PubMed ID: 25681068
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
[TBL] [Abstract][Full Text] [Related]
17. Current trends in the real-life use of dalbavancin: report of a study panel.
Durante-Mangoni E; Gambardella M; Iula VD; De Stefano GF; Corrado MF; Esposito V; Gentile I; Coppola N
Int J Antimicrob Agents; 2020 Oct; 56(4):106107. PubMed ID: 32721599
[TBL] [Abstract][Full Text] [Related]
18. Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.
Leuthner KD; Yuen A; Mao Y; Rahbar A
Expert Rev Anti Infect Ther; 2015 Feb; 13(2):149-59. PubMed ID: 25578881
[TBL] [Abstract][Full Text] [Related]
19. Dalbavancin for the treatment of paediatric infectious diseases.
Esposito S; Bianchini S
Eur J Clin Microbiol Infect Dis; 2016 Dec; 35(12):1895-1901. PubMed ID: 27562407
[TBL] [Abstract][Full Text] [Related]
20. New antibiotics in the management of acute bacterial skin and skin structure infections.
Gleghorn K; Grimshaw E; Kelly EK
Skin Therapy Lett; 2015; 20(5):7-9. PubMed ID: 26382907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
